Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.64), $0.11 better than the analyst estimate of ($1.75). Revenue for the quarter came in at $177.6 million versus the consensus estimate of $168.74 million.

2021 Financial Guidance

Full year 2021 financial guidance is reiterated and consists of the following:

	Combined net product revenues for ONPATTRO, GIVLAARI and OXLUMO		$610 million - $660 million
	Net revenues from collaborations and royalties		$150 million - $200 million
	GAAP R&D and SG&A expenses		$1,335 million - $1,455 million
	Non-GAAP R&D and SG&A expenses*		$1,175 million - $1,275 million

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.